News 2023-06-23
Porton Pharma Solutions Expands Global Reach with New Site in Slovenia and Enhanced Manufacturing Capabilities
Porton Pharma Solutions Ltd. continues to expand its reach globally. Last year, we launched the construction of a new site in Menges, Slovenia. The state-of-the-art GMP manufacturing site will significantly expand Porton’s network beyond China and the US as it sets out to provide solutions to customers and partners in Europe.
Moreover, Porton also started production in its Drug Product cdmo and cell and gene therapy CDMO commercialization facilities. It also began implementing the APS (Advanced Planning and Scheduling) to boost the efficiency in production scheduling and order fulfillment and promote transparency in capacity planning management.
All these production and operation efforts are part of Porton’s commitment to providing high-quality services.
Others
More
News 2025-01-14
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.
News 2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 44 (out of 100) in the 2024 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved. (CSA Score as of 27/11/2024).
